Sacituzumab Tirumotecan: A New Targeted Therapy Improves Survival in EGFR-Mutant Lung Cancer After TKI Resistance

Table of Contents

• Key Points
• Why This Research Matters
• How the Study Was Conducted
• Who Participated in the Trial
• Key Finding: Delaying Cancer Progression
• Key Finding: Improving Overall Survival
• Results Across Patient Subgroups
• Side Effects and Safety Profile
• What This Means for Patients
• Study Limitations
• Recommendations for Patients
• Frequently Asked Questions
• Source Information

Key Points

• In a phase 3 trial of 376 patients, sac-TMT nearly doubled progression-free survival (8.3 vs 4.3 months) versus chemotherapy in EGFR-TKI-resistant lung cancer.
• Sac-TMT reduced the risk of death by 40% compared to chemotherapy, with 18-month survival of 65.8% versus 48.0%.
• The benefit was consistent across most patient subgroups, including age, sex, smoking history, and EGFR mutation subtype.
• Severe side effects were similar (58% vs 54%), but serious adverse events were less common with sac-TMT (9% vs 17.6%).
• The trial enrolled only Asian patients in China; results may not apply to other populations.

Why This Research Matters

Lung cancer remains one of the most challenging cancers to treat. About a quarter of non–small-cell lung cancer (NSCLC) cases carry a mutation in the epidermal growth factor receptor (EGFR) gene, a change that acts like a "gas pedal" driving cancer cell growth. Fortunately, drugs called EGFR tyrosine kinase inhibitors (TKIs) can block this signal.

For patients with advanced EGFR-mutated NSCLC, third-generation EGFR TKIs (like osimertinib) are currently the standard first-line treatment. These drugs work well initially. However, nearly all tumors eventually develop acquired resistance, meaning the drug stops working and the cancer begins to grow again. Once this happens, treatment options become limited.

Platinum-based doublet chemotherapy has been the standard of care in this situation for years. But its effectiveness is modest. Recent trials exploring alternative combinations — such as ivonescimab (a drug targeting both PD-1 and vascular endothelial growth factor), sintilimab (a PD-1 inhibitor) combined with a bevacizumab biosimilar, amivantamab (an EGFR and c-Met bispecific antibody) with or without lazertinib, and HER3-directed antibody–drug conjugates — have shown some improvement in delaying progression. However, clear overall survival benefits have remained uncertain.

This is where sacituzumab tirumotecan (sac-TMT) enters the picture. Sac-TMT belongs to a class of medicines called antibody–drug conjugates (ADCs). Think of an ADC as a "smart bomb": one part is an antibody that seeks out a specific target on cancer cells, and the other part is a powerful chemotherapy drug attached to it.

Sac-TMT targets a protein called trophoblast cell-surface antigen 2 (Trop-2), which sits on the surface of cancer cells. Trop-2 is highly expressed in EGFR-mutated NSCLC, and its presence is linked to resistance to EGFR-TKIs. Among all the antigens that can be targeted with ADCs, Trop-2 is the most strongly and selectively expressed in EGFR-TKI-resistant NSCLC cells. The antibody part of sac-TMT is attached to a belotecan-derived topoisomerase I inhibitor — a drug that interferes with the cancer cell's ability to copy and repair its DNA, causing cell death.

Earlier research supported the promise of this approach. In the phase 1–2 KL264-01 study, sac-TMT showed encouraging antitumor activity in patients with EGFR-TKI-refractory advanced NSCLC who had not received chemotherapy. The phase 2 OptiTROP-Lung03 trial then showed that sac-TMT produced a significant overall survival benefit when compared with docetaxel (a traditional chemotherapy drug). This new phase 3 trial, OptiTROP-Lung04, was designed to confirm those findings on a larger scale.

How the Study Was Conducted

The OptiTROP-Lung04 trial was a phase 3, multicenter, open-label, randomized study. That means it compared two treatments directly, both patients and doctors knew which treatment was being given, and assignment was determined by chance rather than choice. The trial took place at 66 sites across China.

Patients received either sac-TMT alone or the standard chemotherapy regimen. Randomization was done in a 1:1 ratio, meaning each patient had an equal 50/50 chance of getting either treatment. To make the two groups as similar as possible, the researchers used a centralized stratified block randomization system, with stratification factors including previous exposure to third-generation EGFR-TKIs (first-line use, second-line use, or no prior use) and whether the patient had brain metastases.

Treatment details:

• Sac-TMT group: Sac-TMT was given intravenously at a dose of 5 milligrams per kilogram of body weight on day 1 and day 15 of each 28-day cycle.
• Chemotherapy group: Patients received pemetrexed (500 milligrams per square meter of body-surface area) plus the investigator's choice of either carboplatin (dosed to reach an area under the curve of 5) or cisplatin (75 milligrams per square meter). These were given on day 1 of each 21-day cycle for up to four cycles, followed by pemetrexed maintenance therapy.

Treatment continued until disease progression, unacceptable side effects, patient withdrawal, or another protocol-specified reason to stop. Patients in the chemotherapy group were not allowed to switch to sac-TMT during the trial treatment phase. However, because sac-TMT is commercially available, chemotherapy patients could receive it after their disease progressed.

The primary endpoint, or main measure of success, was progression-free survival (PFS) — the length of time a patient lived without the cancer growing — as determined by blinded independent review, meaning the reviewers did not know which treatment each patient had received. Overall survival (how long patients lived) was the key secondary endpoint and was tested in a hierarchical way so the results could be interpreted reliably.

The researchers calculated they needed about 356 patients and a total of 249 progression-or-death events to detect a hazard ratio of 0.67 for progression-free survival with 88% power. That same sample size would give the trial 80% power to detect an overall survival difference assuming a hazard ratio of 0.70.

An interim analysis of progression-free survival was planned after at least 174 events. That analysis, with a data cutoff of July 11, 2024, crossed the prespecified significance boundary (two-sided P<0.0001). The results presented in this article come from the prespecified final analysis of progression-free survival and the preplanned interim analysis of overall survival, both based on a data cutoff of July 6, 2025, at which point 168 deaths had occurred. The statistical boundary for the interim overall survival analysis was a two-sided alpha of 0.0124.

Who Participated in the Trial

Between July 6, 2023, and April 24, 2024, a total of 596 patients were screened for the trial. Of those, 376 were enrolled and randomly assigned: 188 to the sac-TMT group and 188 to the chemotherapy group.

Eligible patients had to be between the ages of 18 and 75 and have histologically or cytologically confirmed locally advanced (stage IIIB or IIIC) or metastatic (stage IV) nonsquamous NSCLC. The cancer had to harbor sensitizing EGFR mutations, including exon 19 deletions or the exon 21 codon p.Leu858Arg (L858R) substitution. Patients qualified if they had progressed after first- or second-generation EGFR-TKIs with a documented T790M-negative status (meaning they did not have the T790M resistance mutation), or if they had progressed after third-generation EGFR-TKIs regardless of T790M status. Patients also needed an Eastern Cooperative Oncology Group (ECOG) performance-status score of 0 or 1 — a scale from 0 to 5 where higher numbers indicate greater disability, with 0 meaning fully active and 1 meaning restricted in physically strenuous activity but still able to walk and work. Patients with brain metastases were eligible if the lesions had been treated and were stable.

The patients' characteristics at the start of the trial (baseline characteristics) were well balanced between the two groups:

• The median age was 60 years (range, 31 to 75); 30.9% of sac-TMT patients and 27.1% of chemotherapy patients were 65 or older.
• Only 39.6% of all patients were men (35.1% in the sac-TMT group, 44.1% in the chemotherapy group).
• All patients were of Asian race, and the trial enrolled only patients in China.
• The majority (74.5%) had never smoked.
• Nearly all patients (97.6%) had stage IV disease at enrollment.
• All patients had an ECOG performance-status score of 0 (20.7%) or 1 (79.3%).
• Brain metastases were present in 17.6% of sac-TMT patients and 19.1% of chemotherapy patients; liver metastases in 13.3% and 17.6%, respectively.
• 68.1% of sac-TMT patients and 67.0% of chemotherapy patients had at least three metastatic sites.
• EGFR mutation subtypes: exon 19 deletion was found in 56.4% of sac-TMT patients and 62.8% of chemotherapy patients; exon 21 L858R substitution in 44.7% and 37.8%, respectively. Some patients had both or other co-occurring mutations.
• 94.7% of patients in each group had previously received third-generation EGFR-TKIs, most often as first-line therapy (62.5%).

As of the July 6, 2025, data cutoff, 40 patients (21.3%) in the sac-TMT group were still receiving their trial treatment, compared with only 3 patients (1.6%) in the chemotherapy group. All 376 patients were included in the main efficacy analysis (the intention-to-treat population). The safety analysis included 188 patients in the sac-TMT group and 182 in the chemotherapy group; 6 patients were excluded from safety analyses because they were randomized but never received their assigned treatment.

Key Finding: Delaying Cancer Progression

After a median follow-up of 18.9 months, the results strongly favored sac-TMT.

Disease progression (confirmed by blinded independent review) or death had occurred in 144 of 188 patients (76.6%) in the sac-TMT group, compared with 159 of 188 patients (84.6%) in the chemotherapy group.

The median progression-free survival was 8.3 months in the sac-TMT group (95% confidence interval [CI], 6.7 to 9.9), compared with 4.3 months in the chemotherapy group (95% CI, 4.2 to 5.5). The hazard ratio for disease progression or death was 0.49 (95% CI, 0.39 to 0.62). In plain terms, this means patients treated with sac-TMT had about a 51% lower risk of their cancer progressing or dying during the study period compared with chemotherapy patients — a very substantial improvement.

The benefit was visible early and grew over time. At 12 months, 32.3% of sac-TMT patients (about 1 in 3) were alive without disease progression, compared with only 7.9% of chemotherapy patients (about 1 in 13). That is an absolute difference of about 24 more patients per 100 remaining free of progression at one year. The most common sites of progression were the lung and the central nervous system.

Importantly, the results assessed by the patients' own investigators were consistent with the blinded independent review, confirming the reliability of the findings.

Key Finding: Improving Overall Survival

The most meaningful question for any cancer patient is simple: does this treatment help me live longer? In this trial, the answer was yes.

Overall survival was significantly longer with sac-TMT than with chemotherapy. The hazard ratio for death was 0.60 (95% CI, 0.44 to 0.82; two-sided P = 0.001). This translates to a 40% lower risk of death for patients in the sac-TMT group. A P value of 0.001 means there is only a 0.1% chance that this survival difference happened by random luck.

The survival advantage was also reflected in the milestone rate. At 18 months, 65.8% of sac-TMT patients were still alive (about 2 in 3), compared with 48.0% of chemotherapy patients (about 1 in 2). That is an absolute difference of about 18 more patients per 100 alive at 18 months.

It is worth noting that this is the preplanned interim analysis of overall survival, not the final one. The results are encouraging, but the data will continue to mature.

Among patients who stopped the trial treatment (148 in the sac-TMT group and 179 in the chemotherapy group), 72.3% and 85.5%, respectively, went on to receive subsequent anticancer treatment. More chemotherapy patients needed follow-up chemotherapy (53.6% vs. 41.9%). Notably, 19.6% of chemotherapy patients later received an antibody–drug conjugate, compared with only 1.4% of sac-TMT patients — likely because sac-TMT itself was serving as the ADC treatment in that group.

Results Across Patient Subgroups

The researchers also examined whether the progression-free survival benefit held across different types of patients. These prespecified subgroup analyses all consistently favored sac-TMT, although the strength of the effect varied:

• Sex: Men, hazard ratio 0.53 (95% CI, 0.37 to 0.76); women, 0.44 (95% CI, 0.33 to 0.60).
• Age: Under 65, 0.46 (95% CI, 0.35 to 0.61); 65 or older, 0.51 (95% CI, 0.33 to 0.78).
• Smoking history: Current or former smokers, 0.56 (95% CI, 0.36 to 0.88); never smokers, 0.44 (95% CI, 0.34 to 0.59).
• ECOG performance status: Score 0, 0.38 (95% CI, 0.22 to 0.65); score 1, 0.50 (95% CI, 0.39 to 0.65).
• Previous third-generation EGFR-TKI use: First-line, 0.48 (95% CI, 0.36 to 0.65); second-line, 0.49 (95% CI, 0.33 to 0.73).
• Brain metastases: Yes, 0.73 (95% CI, 0.43 to 1.21); no, 0.43 (95% CI, 0.33 to 0.56).
• Liver metastases: Yes, 0.54 (95% CI, 0.30 to 0.98); no, 0.46 (95% CI, 0.35 to 0.59).
• EGFR mutation subtype: Exon 21 L858R, 0.57 (95% CI, 0.39 to 0.81); exon 19 deletion, 0.42 (95% CI, 0.31 to 0.57).
• T790M mutation status: Negative, 0.50 (95% CI, 0.30 to 0.83); positive, 0.50 (95% CI, 0.28 to 0.87); unknown, 0.45 (95% CI, 0.33 to 0.61).

The brain-metastasis subgroup deserves an honest explanation. The hazard ratio of 0.73 suggests a benefit, but the confidence interval crosses 1.0 (0.43 to 1.21), which means the result did not reach statistical significance in that smaller group. This could reflect the smaller number of patients with brain metastases (33 in the sac-TMT group and 36 in the chemotherapy group) rather than a lack of benefit.

Side Effects and Safety Profile

Any powerful cancer treatment comes with side effects, and sac-TMT is no exception. The safety analysis included 188 patients who received sac-TMT and 182 who received chemotherapy.

Treatment-related adverse events of grade 3 or higher (meaning severe, medically significant side effects) occurred in 58.0% of sac-TMT patients (about 58 in 100) and in 53.8% of chemotherapy patients (about 54 in 100). The overall rates were similar, but the types of side effects differed.

The most common severe side effect in both groups was a decreased neutrophil count (neutropenia), a type of white blood cell that helps fight infections:

• Sac-TMT group: 39.9% (about 40 in 100)
• Chemotherapy group: 33.0% (33 in 100)

Treatment-related serious adverse events — side effects bad enough to require hospitalization or cause significant disability — were actually less common with sac-TMT:

• Sac-TMT group: 9.0% (about 9 in 100, or roughly 17 of 188 patients)
• Chemotherapy group: 17.6% (about 18 in 100, or roughly 32 of 182 patients)

Because neutropenia was the most common severe side effect, patients receiving sac-TMT will need regular blood count monitoring. Dose reductions to manage side effects were permitted in the trial, which is standard oncology practice. Overall, the safety profile of sac-TMT was considered manageable and consistent with what has been seen in earlier studies of this drug.

What This Means for Patients

This trial provides strong evidence of a new treatment option for a very common and difficult clinical scenario: EGFR-mutant lung cancer that has stopped responding to EGFR-TKI therapy.

Before this trial, patients in this situation were typically offered platinum-based chemotherapy, with modest results. Sac-TMT offers a genuinely better alternative. It nearly doubled the median time before cancer progression, from 4.3 months to 8.3 months. It also produced a 40% reduction in the risk of death, with a striking difference in 18-month survival: 65.8% versus 48.0%.

The fact that 94.7% of enrolled patients had already received a third-generation EGFR-TKI — most as first-line therapy — means the results apply directly to today's typical patient population. This trial was conducted in China and enrolled only Asian patients, but the findings are expected to inform treatment decisions globally.

For lung cancer specialists, sac-TMT now joins a small list of evidence-based options for TKI-resistant NSCLC. The confirmation of both a progression-free survival and an overall survival benefit distinguishes this drug from other approaches that have shown only delays in progression without clear survival gains. The consistency of the benefit across nearly all subgroups — regardless of age, sex, smoking history, EGFR mutation subtype, or T790M status — suggests that sac-TMT works broadly within the EGFR-mutant population.

Study Limitations

It is important to look at this study with a critical eye. Several limitations should be kept in mind:

• Open-label design: Both patients and doctors knew which treatment was being given. This can introduce bias, although the use of blinded independent review for the primary endpoint helps reduce that risk.
• Interim overall survival data: The overall survival results come from a preplanned interim analysis, not the final analysis. The benefit is clear and statistically significant, but the magnitude may change as more data mature.
• Limited population: The trial was conducted only in China and enrolled only Asian patients. While the results are strong, additional data in non-Asian populations would be valuable.
• Brain metastasis uncertainty: The benefit in patients with brain metastases did not reach statistical significance (hazard ratio 0.73; 95% CI, 0.43 to 1.21). This may be due to the small number of such patients, but it means we have less certainty about sac-TMT's effectiveness in this subgroup.
• No direct comparison with newer alternatives: The trial compared sac-TMT with platinum-based chemotherapy, not with other emerging regimens such as amivantamab combinations or other antibody–drug conjugates. Head-to-head data would help clarify the best sequencing of treatments.
• Limited follow-up: With a median follow-up of 18.9 months, long-term durability of the treatment response and long-term side effects are not yet fully defined.

Recommendations for Patients

If you or a loved one has EGFR-mutant advanced non–small-cell lung cancer that has progressed after EGFR-TKI therapy, here are some practical steps to consider:

1. Have a conversation about sac-TMT. Ask your oncologist whether sacituzumab tirumotecan might be an appropriate option for your specific situation. The strongest evidence currently supports its use after progression on EGFR-TKI therapy.
2. Know your mutation status. This trial enrolled patients with exon 19 deletions and exon 21 L858R mutations, the two most common sensitizing EGFR mutations. Confirm which mutation your tumor carries and bring that information to your treatment discussion.
3. Discuss your TKI history. The trial included patients who progressed after first-, second-, or third-generation EGFR-TKIs, regardless of T790M status. Your prior treatment history matters for determining whether you fit the profile of patients who benefited.
4. Ask about blood count monitoring. Low neutrophil counts were the most common severe side effect, affecting about 40% of sac-TMT patients. Regular blood tests can detect this early, and dose adjustments are possible if needed.
5. Weigh the practical benefits. Sac-TMT is given intravenously on day 1 and day 15 of each 28-day cycle. Consider how this schedule fits into your life, and discuss any logistical concerns with your care team.
6. Ask about clinical trials. If sac-TMT is not available or suitable for you, ask your oncologist about other clinical trials for EGFR-TKI-resistant lung cancer. The treatment landscape is evolving quickly.

As always, every patient is different. Treatment decisions should be made jointly with your oncology team, based on your specific tumor characteristics, overall health, personal preferences, and the availability of treatments in your region.

Frequently Asked Questions

What is sacituzumab tirumotecan (sac-TMT) and how does it work?

Sac-TMT is an antibody-drug conjugate, a 'smart bomb' that targets a protein called Trop-2 on cancer cells. It delivers a chemotherapy drug directly to the cancer, interfering with DNA copying and repair, causing cell death. In this trial, it was given intravenously on days 1 and 15 of each 28-day cycle.

How much longer did sac-TMT delay cancer progression compared to chemotherapy?

In this trial, sac-TMT nearly doubled the time before cancer worsened. The median progression-free survival was 8.3 months with sac-TMT versus 4.3 months with chemotherapy. This means patients on sac-TMT had about a 51% lower risk of progression or death during the study period.

Did sac-TMT improve overall survival?

Yes. In this trial, sac-TMT reduced the risk of death by 40% compared to chemotherapy. At 18 months, 65.8% of sac-TMT patients were alive versus 48.0% of chemotherapy patients. These results are from an interim analysis, so the final survival benefit may change as more data mature.

What are the common side effects of sac-TMT?

The most common severe side effect was a low neutrophil count (neutropenia), affecting about 40% of sac-TMT patients. Overall, severe side effects occurred in 58% of sac-TMT patients, similar to chemotherapy. However, serious side effects requiring hospitalization were less common with sac-TMT (9% vs 17.6%).

Is sac-TMT effective for patients with brain metastases?

In this trial, the benefit for patients with brain metastases did not reach statistical significance (hazard ratio 0.73, confidence interval crossing 1.0). This may be due to the small number of such patients. More research is needed to confirm effectiveness in this subgroup.

What should I discuss with my oncologist about sac-TMT?

Ask whether sac-TMT is appropriate for your specific situation, especially if you have EGFR-mutant lung cancer that progressed after TKI therapy. Discuss your mutation status, prior TKI history, and the need for regular blood count monitoring. Also consider the treatment schedule and any logistical concerns.

When should a patient with EGFR-mutant lung cancer that has progressed on EGFR-TKI therapy seek a second opinion about sacituzumab tirumotecan?

A second opinion is valuable when your tumor has progressed on EGFR-TKI therapy and you are considering sacituzumab tirumotecan (sac-TMT). In a phase 3 trial, sac-TMT nearly doubled progression-free survival (8.3 vs. 4.3 months) and reduced the risk of death by 40% compared with chemotherapy. Because treatment decisions depend on your specific EGFR mutation, prior TKI history, and overall health, an independent expert review can help confirm whether sac-TMT is appropriate for you and discuss alternatives. Diagnostic Detectives Network provides independent expert second opinions.

Source Information

Original article: "Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR-Mutated Advanced NSCLC" by W. Fang, L. Wu, X. Meng, Y. Yao, W. Zuo, W. Yao, Y. Xie, Yu Zhang, J. Cui, Yongchang Zhang, X. Li, W. Zhuang, J. Fang, Q. Wang, W. Jiang, K. Li, Y. Bai, Y. Luo, F. Ma, Y. Yu, W. Zheng, Z. Liu, B. Yang, R. Ma, Y. Fang, R. Yang, L. Jiang, J. Hu, J. Yang, Y. Diao, X. Jin, J. Ge, Y. Yang, and L. Zhang.

Journal: The New England Journal of Medicine, January 1, 2026, Volume 394, Number 1, pages 13–26. Published online October 19, 2025.

DOI: 10.1056/NEJMoa2512071

Trial registration: OptiTROP-Lung04, ClinicalTrials.gov number NCT05870319. Funded by Sichuan Kelun-Biotech Biopharmaceutical.

This patient-friendly article is based on peer-reviewed research published in The New England Journal of Medicine. It is intended for educational purposes and is not a substitute for professional medical advice. Please consult your healthcare provider about any treatment decisions.